JP7772718B2 - ガレクチン－３阻害剤 - Google Patents
ガレクチン－３阻害剤Info
- Publication number
- JP7772718B2 JP7772718B2 JP2022572736A JP2022572736A JP7772718B2 JP 7772718 B2 JP7772718 B2 JP 7772718B2 JP 2022572736 A JP2022572736 A JP 2022572736A JP 2022572736 A JP2022572736 A JP 2022572736A JP 7772718 B2 JP7772718 B2 JP 7772718B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- chloro
- triazol
- oxoisoindolin
- conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030968P | 2020-05-28 | 2020-05-28 | |
| US63/030,968 | 2020-05-28 | ||
| PCT/US2021/034454 WO2021242982A1 (en) | 2020-05-28 | 2021-05-27 | Galectin-3 inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023527396A JP2023527396A (ja) | 2023-06-28 |
| JP2023527396A5 JP2023527396A5 (https=) | 2024-06-03 |
| JPWO2021242982A5 JPWO2021242982A5 (https=) | 2024-06-03 |
| JP7772718B2 true JP7772718B2 (ja) | 2025-11-18 |
Family
ID=76502884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572736A Active JP7772718B2 (ja) | 2020-05-28 | 2021-05-27 | ガレクチン－３阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12291522B2 (https=) |
| EP (1) | EP4157833A1 (https=) |
| JP (1) | JP7772718B2 (https=) |
| KR (1) | KR20230018431A (https=) |
| CN (1) | CN115768768A (https=) |
| WO (1) | WO2021242982A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026002250A1 (zh) * | 2024-06-28 | 2026-01-02 | 上海济煜医药科技股份有限公司 | 四唑基取代的吡喃半乳糖苷衍生物及其制备方法和应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019014429A1 (en) | 2017-07-12 | 2019-01-17 | Dana-Farber Cancer Institute, Inc. | COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| WO2019173516A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| WO2020038415A1 (en) | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| JP6904906B2 (ja) | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| ES2921500T3 (es) | 2015-11-09 | 2022-08-26 | Galecto Biotech Ab | 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| JP7190513B2 (ja) | 2018-06-15 | 2022-12-15 | ブリストル－マイヤーズ スクイブ カンパニー | ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類 |
-
2021
- 2021-05-27 EP EP21733338.4A patent/EP4157833A1/en active Pending
- 2021-05-27 KR KR1020227045460A patent/KR20230018431A/ko active Pending
- 2021-05-27 CN CN202180038169.4A patent/CN115768768A/zh active Pending
- 2021-05-27 US US17/927,426 patent/US12291522B2/en active Active
- 2021-05-27 WO PCT/US2021/034454 patent/WO2021242982A1/en not_active Ceased
- 2021-05-27 JP JP2022572736A patent/JP7772718B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| WO2019014429A1 (en) | 2017-07-12 | 2019-01-17 | Dana-Farber Cancer Institute, Inc. | COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| WO2019173516A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| WO2020038415A1 (en) | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
Non-Patent Citations (1)
| Title |
|---|
| Ross, Ashleigh R，Exploring Novel Approaches Towerds Anti-Cancer Galectin-3 Chemotherapeutics，Griffith Theses [online]，Griffith University，2020年05月01日，[retrieved on 2025-04-02]. Retrieved from the Internet: <DOI:10.25904/1912/1361> |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023527396A (ja) | 2023-06-28 |
| EP4157833A1 (en) | 2023-04-05 |
| US12291522B2 (en) | 2025-05-06 |
| US20230303538A1 (en) | 2023-09-28 |
| WO2021242982A1 (en) | 2021-12-02 |
| CN115768768A (zh) | 2023-03-07 |
| KR20230018431A (ko) | 2023-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7580136B2 (ja) | Ｊａｋ阻害剤化合物及びその使用 | |
| JP7010935B2 (ja) | Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換ヘテロ環 | |
| CN110520423B (zh) | 作为激酶抑制剂的氨基三唑并吡啶 | |
| CA3216163A1 (en) | Carboxy-benzimidazole glp-1r modulating compounds | |
| JP7577682B2 (ja) | ガレクチン－３の低分子阻害剤 | |
| JP7307734B2 (ja) | キナーゼ阻害剤としてのアミノピロロトリアジン | |
| JP7612663B2 (ja) | （２－アセタミジル）チオ－ベータ－ｄ－ガラクトピラノシド誘導体 | |
| TWI833819B (zh) | 用於治療與apj受體活性相關的病狀的化合物及組成物 | |
| CN117715906A (zh) | 胰高血糖素样肽-1受体调节剂及其用途 | |
| JP2023533783A (ja) | ヒストン脱アセチル化酵素６阻害剤としての新規な構造の化合物およびこれを含む薬剤学的組成物 | |
| CN106687446A (zh) | 作为t790m/wt‑egfr的选择性和不可逆的激酶抑制剂的5‑氨基‑4‑氨甲酰基‑吡唑化合物及其用途 | |
| JP7478165B2 (ja) | ガレクチン－３の低分子阻害剤 | |
| US20250289820A1 (en) | Non-covalent modifiers of akt1 and uses thereof | |
| CN114980975A (zh) | 二氢环戊二烯并异喹啉磺酰胺衍生物 | |
| JP7772718B2 (ja) | ガレクチン－３阻害剤 | |
| CN112513041A (zh) | 三环化合物 | |
| HK40061670A (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
| HK40111351A (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
| HK40128198A (zh) | 用於治疗与apj受体活性有关的疾病的化合物和组合物 | |
| CN113166122A (zh) | 半乳糖凝集素-3的小分子抑制剂 | |
| HK40039964A (en) | Tricyclic compounds | |
| HK40061670B (zh) | 用於治疗与apj受体活性有关的疾病的化合物和组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240524 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240524 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20241115 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250417 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250716 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251014 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251106 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7772718 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |